Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: ArteraAI
Related tests:


Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform (Businesswire)
"Artera...will present three abstracts at the 2024 ASCO Annual Meeting demonstrating that its multimodal artificial intelligence (MMAI) platform provides significant prognostic value across various stages of prostate cancer and for early stage breast cancer. These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test...The MMAI platform can provide results to support personalized therapy by combining a patient’s unique clinical data with their pathology slides. Artera is taking a unique approach to this by applying AI to images of hematoxylin and eosin (H&E)-stained pathology slides to provide prognostic and predictive results."
Clinical data
ArteraAI Prostate Test
New data validating the first AI-based biomarker to stratify risk of metastasis in radical prostatectomy patients with biochemical recurrence (Businesswire)
"ArteraAI...announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR)."
Clinical data
ArteraAI and Movember announce new relationship (Businesswire)
"ArteraAI...announced its continued work with Movember...This announcement follows a recent study presented at the 2023 European Society for Medical Oncology Congress (ESMO). The study successfully validated ArteraAI's prognostic model in advanced prostate cancer, demonstrating stronger prognostic correlations than individual clinical factors."
Licensing / partnership
ArteraAI Announced as the First-and-Only Predictive Test for Therapy Personalization in the 2024 NCCN Guidelines for Prostate Cancer (Businesswire)
"ArteraAI...announced today its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance. The test is also the first AI-enabled predictive and prognostic test to be recommended in the guidelines for localized prostate cancer."
NCCN guideline
ArteraAI Prostate Test
ArteraAI secures $20 million in funding to further personalize cancer therapy with multimodal AI (Businesswire)
"ArteraAI...announced today that it has secured an additional $20 million in capital fueled by several prominent large investment funds including Prosperity7 Ventures, Singapore-based global investor EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, along with investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC)."
ArteraAI receives Medicare payment rate for the ArteraAI Prostate cancer test (Businesswire)
"ArteraAI...announced today that the Centers for Medicare and Medicaid Services (CMS) have decided on the payment rate for the ArteraAI Prostate Test, a Clinical Diagnostic Laboratory Test (CDLT). The rate became effective on Jan. 1, 2024."
ArteraAI announces research agreement with CorePlus (Businesswire)
"ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today a research agreement with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory headquartered in Carolina, Puerto Rico. The collaboration aims to further validate The ArteraAI Prostate Test in the Hispanic population."
Licensing / partnership